Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by Wide Margin; Guides FY23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance
March 1, 2023 4:05 PM ESTStrong Execution Drove Record Revenues in 2022 of $3.7 billion, an increase of 18% over 2021Positioned for Total Revenue and Net Income Growth in 2023 Â Xywav Enters 2023 as the Oxybate Therapy of Choice and Company's Largest Product by Net SalesEnhanced Investment in R&D to Advance Pipeline towards Key Value Inflection Points in 2023 and 2024Company is Well-Positioned to Achieve Vision 2025
DUBLIN, March 1, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the... More
